Which has higher earnings & valuation, GLAS or NRXP?

NRx Pharmaceuticals has lower revenue, but higher earnings than Glass House Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $181.98M 2.18 -$29.66M N/A N/A NRx Pharmaceuticals $1.23M 100.33 -$28.62M -$0.55 N/A

Is NRXP or OCS more profitable?

NRx Pharmaceuticals has a net margin of -691.81% compared to Oculis' net margin of -6,777.18%. NRx Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Oculis -6,777.18% -42.61% -35.23%

Does the media favor NRXP or OCS?

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Oculis. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 6 mentions for Oculis. Oculis' average media sentiment score of 0.37 beat NRx Pharmaceuticals' score of -0.28 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NRXP or TLRY?

In the previous week, Tilray Brands had 22 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 37 mentions for Tilray Brands and 15 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.29 beat NRx Pharmaceuticals' score of -0.28 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 7 Very Positive mention(s) 10 Positive mention(s) 10 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NRXP or CTNM?

In the previous week, NRx Pharmaceuticals had 11 more articles in the media than Contineum Therapeutics. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of -0.10 beat NRx Pharmaceuticals' score of -0.28 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NRXP or DRUG?

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat NRx Pharmaceuticals' score of -0.28 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

NRx Pharmaceuticals (NRXP) Competitors

$2.85 -0.04 (-1.38%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.85 +0.00 (+0.07%)

As of 10/9/2026 08:00 PM Eastern

Compare

NRXP vs. GLAS, OCS, TLRY, CTNM, and DRUG

Should you buy NRx Pharmaceuticals stock or one of its competitors? NRx Pharmaceuticals's main competitors and comparable companies include Glass House Brands (GLAS), Oculis (OCS), Tilray Brands (TLRY), Contineum Therapeutics (CTNM), and Bright Minds Biosciences (DRUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NRx Pharmaceuticals compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, NRx Pharmaceuticals had 14 more articles in the media than Glass House Brands. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 1 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.28 indicating that Glass House Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Glass House Brands	Neutral
NRx Pharmaceuticals	Neutral

Glass House Brands currently has a consensus price target of $16.00, indicating a potential upside of 274.80%. NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 1,110.53%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

NRx Pharmaceuticals has lower revenue, but higher earnings than Glass House Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$181.98M	2.18	-$29.66M	N/A	N/A
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A

Glass House Brands has a net margin of -29.48% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	-29.48%	-58.76%	-15.14%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NRx Pharmaceuticals beats Glass House Brands on 9 of the 13 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Oculis?

NRx Pharmaceuticals (NASDAQ:NRXP) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

NRx Pharmaceuticals has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market. Comparatively, Oculis has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

NRx Pharmaceuticals has a net margin of -691.81% compared to Oculis' net margin of -6,777.18%. NRx Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Oculis	-6,777.18%	-42.61%	-35.23%

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Oculis. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 6 mentions for Oculis. Oculis' average media sentiment score of 0.37 beat NRx Pharmaceuticals' score of -0.28 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 1,110.53%. Oculis has a consensus target price of $39.44, suggesting a potential upside of 372.95%. Given NRx Pharmaceuticals' higher possible upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

NRx Pharmaceuticals has higher earnings, but lower revenue than Oculis. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A
Oculis	$1.45M	333.48	-$119.44M	-$1.74	N/A

Summary

NRx Pharmaceuticals and Oculis tied by winning 8 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Tilray Brands?

NRx Pharmaceuticals (NASDAQ:NRXP) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

NRx Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A
Tilray Brands	$915.45M	0.53	-$121.40M	-$1.08	N/A

Tilray Brands has a net margin of -16.91% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Tilray Brands	-16.91%	-10.47%	-7.52%

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NRx Pharmaceuticals currently has a consensus price target of $34.50, suggesting a potential upside of 1,110.53%. Tilray Brands has a consensus price target of $5.90, suggesting a potential upside of 66.67%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tilray Brands	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.38

In the previous week, Tilray Brands had 22 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 37 mentions for Tilray Brands and 15 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.29 beat NRx Pharmaceuticals' score of -0.28 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	7 Very Positive mention(s)	10 Positive mention(s)	10 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Summary

NRx Pharmaceuticals beats Tilray Brands on 9 of the 17 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Contineum Therapeutics?

NRx Pharmaceuticals (NASDAQ:NRXP) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

NRx Pharmaceuticals has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Contineum Therapeutics	N/A	-24.73%	-23.51%

In the previous week, NRx Pharmaceuticals had 11 more articles in the media than Contineum Therapeutics. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 4 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of -0.10 beat NRx Pharmaceuticals' score of -0.28 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 1,110.53%. Contineum Therapeutics has a consensus target price of $22.17, suggesting a potential upside of 65.67%. Given NRx Pharmaceuticals' higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A
Contineum Therapeutics	$50M	10.07	-$59.98M	-$1.73	N/A

Summary

NRx Pharmaceuticals beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Bright Minds Biosciences?

NRx Pharmaceuticals (NASDAQ:NRXP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 15 mentions for NRx Pharmaceuticals and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat NRx Pharmaceuticals' score of -0.28 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NRx Pharmaceuticals presently has a consensus price target of $34.50, indicating a potential upside of 1,110.53%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 166.11%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Bright Minds Biosciences has lower revenue, but higher earnings than NRx Pharmaceuticals. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	100.33	-$28.62M	-$0.55	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

NRx Pharmaceuticals has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.22, meaning that its share price is 622% less volatile than the broader market.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bright Minds Biosciences has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Summary

Bright Minds Biosciences beats NRx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXP vs. The Competition

Export

Metric	NRx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.12M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-5.18	797.58	274.15	26.16
Price / Sales	100.33	757.87	590.48	94.54
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-5.28	10.71	11.21	6.34
Net Income	-$28.62M	$2.84B	$3.50B	$381.90M
7 Day Performance	-1.72%	-0.93%	-0.90%	-1.41%
1 Month Performance	-16.18%	-4.91%	-4.44%	-3.48%
1 Year Performance	-10.09%	-4.13%	6.96%	1.16%

NRx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXP NRx Pharmaceuticals	2.0089 of 5 stars	$2.85 -1.4%	$34.50 +1,110.5%	-19.9%	$125.12M	$1.23M	N/A	29	Analyst Revision
GLAS Glass House Brands	2.1485 of 5 stars	$5.36 +0.7%	$16.00 +198.8%	N/A	$502.30M	$181.98M	N/A	357	Short Interest Increase
OCS Oculis	2.1464 of 5 stars	$8.63 -1.5%	$39.44 +357.1%	-60.5%	$500.37M	$1.45M	N/A	60
TLRY Tilray Brands	4.1922 of 5 stars	$3.62 +1.3%	$7.00 +93.6%	-83.1%	$492.36M	$915.45M	N/A	3,595	Trending News Analyst Upgrade
CTNM Contineum Therapeutics	2.6071 of 5 stars	$12.94 -0.4%	$22.17 +71.4%	+10.0%	$486.62M	$50M	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. GLAS, OCS, TLRY, CTNM, and DRUG

How does NRx Pharmaceuticals compare to Glass House Brands?

Summary

How does NRx Pharmaceuticals compare to Oculis?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Summary

How does NRx Pharmaceuticals compare to Contineum Therapeutics?

Summary

How does NRx Pharmaceuticals compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. GLAS, OCS, TLRY, CTNM, and DRUG

How does NRx Pharmaceuticals compare to Glass House Brands?

Does the media favor GLAS or NRXP?

Do analysts recommend GLAS or NRXP?

Which has higher earnings & valuation, GLAS or NRXP?

Is GLAS or NRXP more profitable?

Do institutionals & insiders have more ownership in GLAS or NRXP?

Summary

How does NRx Pharmaceuticals compare to Oculis?

Which has more volatility and risk, NRXP or OCS?

Is NRXP or OCS more profitable?

Does the media favor NRXP or OCS?

Do insiders & institutionals have more ownership in NRXP or OCS?

Do analysts rate NRXP or OCS?

Which has preferable earnings and valuation, NRXP or OCS?

Summary

How does NRx Pharmaceuticals compare to Tilray Brands?

Which has preferable valuation & earnings, NRXP or TLRY?

Is NRXP or TLRY more profitable?

Do insiders & institutionals have more ownership in NRXP or TLRY?

Do analysts prefer NRXP or TLRY?

Does the media refer more to NRXP or TLRY?

Which has more risk & volatility, NRXP or TLRY?

Summary

How does NRx Pharmaceuticals compare to Contineum Therapeutics?

Which has more risk & volatility, NRXP or CTNM?

Do insiders & institutionals hold more shares of NRXP or CTNM?

Is NRXP or CTNM more profitable?

Does the media favor NRXP or CTNM?

Do analysts rate NRXP or CTNM?

Which has stronger valuation & earnings, NRXP or CTNM?

Summary

How does NRx Pharmaceuticals compare to Bright Minds Biosciences?

Does the media favor NRXP or DRUG?

Do analysts rate NRXP or DRUG?

Which has preferable earnings and valuation, NRXP or DRUG?

Which has more risk & volatility, NRXP or DRUG?

Do insiders & institutionals have more ownership in NRXP or DRUG?

Is NRXP or DRUG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools